first ESC cardio oncology guidelines, uses LVEF and monitoring CV damage. Future actions suggest further refining monitoring and management.
https://pubmed.ncbi.nlm.nih.gov/36017568/
1. Will V02 Peak be recognised by industry as a valid CV marker?
2. Also, will upfront preventative treatment be adopted rather than reactive management?
3. Will adoption be taken for all anthracycline patients or simply ‘high risk’ as per ESC.
4. Are ESC merely guidelines, what do / will oncologists follow?
-
- There are more pages in this discussion • 349 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.005(0.44%) |
Mkt cap ! $196.3M | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.12 | $202.7K | 178.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 22685 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 12644 | 3 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |